銅ベースの金属有機構造は,動的にバランスのとれた細胞リドックスホメオスタシスをシステム的に破壊することによって,がんの化学抵抗を克服する
Jia Liu1, Ye Yuan1,2, Yanni Cheng1
1Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Journal of the American Chemical Society
|February 22, 2022
まとめ
新しい銅基金属有機フレームワーク (CuHPT) は,薬剤耐性がん細胞を標的とし,その酸化還元恒常性を破壊し,酸化ストレスを誘発し,がん細胞を選択的に殺します. このアプローチは,化学抵抗を克服するための臨床前モデルの有意な可能性を示しています.
科学分野:
- 生物医学工学
- 材料科学
- 腫瘍学
背景:
- 化学薬品耐性はがんの再発の主な要因で 複雑な細胞メカニズムによって悪化することが多い
- 従来の治療法では 耐性がんに対して 失敗することが多く 時には代替治療法によって 耐性を促進することさえあります
研究 の 目的:
- 薬剤耐性の癌細胞の 独特の生化学的脆弱性を標的とした 新しい治療剤を設計する
- 化学薬品耐性を克服するための銅基金属有機構造 (CuHPT) の可能性を調査する.
主な方法:
- ナノサイズの銅/カテコール基の金属有機枠組 (CuHPT) の開発
- ガン細胞内でグルタチオン (GSH) によって誘発されるCuHPTの分解メカニズムの調査.
- ROS生成とGSH減少による酸化ストレスを誘発するCuHPTの能力の評価.
- 薬剤耐性がん細胞に対するCuHPTの細胞毒性の評価 in vitro および in vivo 腫瘍成長抑制.
主要な成果:
- CuHPTは薬剤耐性細胞で選択的に分解し,銅イオンとカテキルリガンドを放出する.
- 分解は,GSHを枯渇させ,酸化ストレスを引き起こすことで,細胞内活性酸素種 (ROS) の生成を拡大する.
- CuHPTは,複数の薬剤耐性がん細胞系に対して強力で選択的な細胞毒性を示した.
- 生体内試験では,CuHPTは腫瘍の成長を効果的に抑制し,マウスの生存率を大幅に改善しました.
結論:
- CuHPTは薬剤耐性の癌細胞の 還元性恒常性を正確に分解することで 賢い治療薬として作用します
- この新しい銅ベースのMOFは,化学抵抗を克服し,がん治療結果を改善するための有望な戦略を提供します.
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Adaptive Mechanisms in Cancer Cells
6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Electron Transport Chain: Complex I and II
15.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.2K
Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K


